Forward genetic screens are powerful tools for the unbiased discovery and functional characterization of specific genetic elements associated with a phenotype of interest. recently, the rna-guided endonuclease cas9 from the microbial crIspr (clustered regularly interspaced short palindromic repeats) immune system has been adapted for genome-scale screening by combining cas9 with pooled guide rna libraries. Here we describe a protocol for genome-scale knockout and transcriptional activation screening using the crIspr-cas9 system. custom-or ready-made guide rna libraries are constructed and packaged into lentiviral vectors for delivery into cells for screening. as each screen is unique, we provide guidelines for determining screening parameters and maintaining sufficient coverage. to validate candidate genes identified by the screen, we further describe strategies for confirming the screening phenotype, as well as genetic perturbation, through analysis of indel rate and transcriptional activation. Beginning with library design, a genome-scale screen can be completed in 9-15 weeks, followed by 4-5 weeks of validation.
IntroDuctIon
Systematic and high-throughput genetic perturbation technologies within live model organisms are necessary for fully understanding gene function and epigenetic regulation [1] [2] [3] . Forward genetic screens allow for a 'phenotype-to-genotype' approach to mapping specific genetic perturbations to a phenotype of interest. Generally, this involves perturbing many genes at once, selecting cells or organisms for a desired phenotype, and then sequencing the perturbations to identify the genetic features involved in the phenotypic change. Early screening approaches relied on chemical DNA mutagens to induce genetic changes, but this process was inefficient and mutations were costly to identify. More recently, tools that use the RNA interference (RNAi) pathway, specifically short hairpin RNAs (shRNAs) [4] [5] [6] [7] , to perturb transcript levels have revolutionized screening approaches [8] [9] [10] [11] [12] [13] . ShRNAs exploit the endogenous RNAi machinery to knock down sequence-complementary mRNAs (Fig. 1) . Despite the contribution of RNAi screens to many biological advances, this approach is hampered by incomplete knockdown of transcripts and high off-target activity, resulting in a low signal-to-noise ratio and limited interpretations [14] [15] [16] .
Cas9 as a tool for precise genome editing
Programmable nucleases have emerged as a promising new genetic perturbation technology capable of precisely recognizing and cleaving target DNA [17] [18] [19] . Particularly, the RNA-guided endonuclease Cas9 from the microbial CRISPR immune system has proven powerful for precise DNA modifications [20] [21] [22] [23] [24] [25] . Cas9 is guided to specific genomic targets by short RNAs that form Watson-Crick base pairs with the DNA. Thus, Cas9 is easily retargetable.
Cas9 generates precise double-strand breaks (DSBs) at target loci that are repaired through either homology-directed repair or, more often, nonhomologous end-joining (NHEJ) 26 . Homologydirected repair precisely repairs the DSB using a homologous DNA template, whereas NHEJ is error-prone and introduces indels. When Cas9 is targeted to a coding region, loss-of-function (LOF) mutations can occur as a result of frameshifting indels that produce a premature stop codon and subsequent nonsensemediated decay of the transcript or generate a nonfunctional protein ( Fig. 1) 24, 25 . These features make Cas9 ideal for genomeediting applications.
Transcriptional activation with Cas9
In addition to generating LOF mutations, Cas9 can modulate transcription without modifying the genomic sequence through fusing catalytically inactive Cas9 (dCas9) to transcriptional activation and repression domains [27] [28] [29] [30] [31] [32] [33] [34] . CRISPR activation (CRISPRa) and CRISPR inhibition (CRISPRi) can be achieved by direct fusion or recruitment of activation and repression domains, such as VP64 and KRAB, respectively 29, 35 . CRISPRa in particular offers a substantial improvement as a screening platform over other activation approaches. Previously, gain-of-function (GOF) screens were primarily limited to cDNA overexpression libraries, which suffered from incomplete representation, overexpression beyond physiological levels and endogenous regulation, lack of isoform diversity, and high cost of construction. CRISPRa overcomes these limitations because it activates gene transcription at the endogenous locus and simply requires the synthesis and cloning of RNA guides, making it much more affordable.
The first generation of CRISPRa fused dCas9 to a VP64 or p65 activation domain to produce modest transcriptional upregulation, the range of which was not suitable for genome-scale screening 29, [31] [32] [33] 35 . Second-generation CRISPRa designs produced more robust upregulation by recruiting multiple activation domains to the dCas9 complex. For instance, SunTag recruits multiple VP64 activation domains via a repeating peptide array of epitopes paired Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening with single-chain variable fragment antibodies 28 . Another activation method, fuses three activation domains, VP64-p65-Rta (VPR), in tandem to dCas9 to enhance transcriptional activation 27 .
We devised an alternative approach to CRISPRa that involves incorporating MS2 binding loops into the sgRNA backbone to recruit two different activation domains, p65 and HSF1, to a dCas9-VP64 fusion (Fig. 1) 30 . By recruiting three distinct transcriptional effectors, this synergistic activation mediator (SAM) complex could robustly and reliably drive transcriptional upregulation. A comparison of SunTag, VPR, and SAM across various cell types and species suggested that SAM induced more potent activation in some contexts, but further analysis is needed to determine which approach is most effective for GOF screening 36 .
Applications of CRISPR-Cas9 screening
Together with large pooled single-guide RNA (sgRNA) libraries, Cas9 can mediate high-throughput LOF and GOF dissection of many selectable phenotypes and investigate complex biological questions. As a proof of principle to demonstrate the CRISPRCas9 system's utility for screening, we constructed genome-scale CRISPR-Cas9 knockout (GeCKO) and SAM libraries to identify genes that, upon knockout or activation, confer resistance to the BRAF inhibitor vemurafenib in a melanoma cell line 30, 37 . In addition to vemurafenib resistance, CRISPR-Cas9 screens have provided insight into the molecular basis of gene essentiality, drug and toxin resistance, the hypoxia response, and the role of flavivirus host factors in infection 28, 30, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Although most screens have been performed in in vitro systems, the Cas9 system has also been applied ex vivo in dendritic cells to study the bacterial lipopolysaccharides response and in vivo to identify key factors that allow a nonmetastatic lung cancer cell line to metastasize 42, 44 . CRISPR-Cas9 screens have also been expanded to the noncoding genome through saturated mutagenesis by tiling sgRNAs across a noncoding locus to uncover functional elements in the BCL11A enhancer, POU5F1 locus, and CUL3 locus, as well as p53 and ESR1 transcription-factor-binding sites [53] [54] [55] [56] [57] . Table 1) .
Here we explain in detail how to set up and perform pooled genome-scale knockout and transcriptional activation screens using Cas9. We describe protocols for designing and cloning an sgRNA library, packaging lentiviral vectors for transduction, analyzing screening results, and validating candidate genes identified by the screen (Fig. 2) . Although we specifically focus on knockout and activation screening using the GeCKO and SAM systems, the protocol can be applied to other types of screens (e.g., other CRISPRa systems, Cas9 knockdown, and saturated mutagenesis).
Comparison with other pooled screening technologies
Although both shRNA and Cas9 are easily retargetable, extensive characterization has shown that Cas9 is much more robust and specific than shRNA 37, [58] [59] [60] [61] . A comparison of GeCKO with shRNA screening indicated that, for guides targeting the same gene, GeCKO results were more consistent and had higher validation rates 37 . For LOF screening to identify essential genes, Cas9 knockout screening has been shown to be more consistent and effective than shRNA screening 61 . Cas9 knockout screening consistently identified more lethal genes than did shRNA, indicating a lower false-negative rate and suggesting that identification of cellular dependencies may require complete gene inactivation 62 .
At the same time, however, in amplified regions of cancer cell genomes, DSBs generated by the Cas9 nuclease can produce gene-independent DNA damage phenotypes and false-positive results 45, 62, 63 . Cas9 knockout screens that target the 5′ exons of candidate genes may produce in-frame variants that retain functionality and obscure genetic dependencies, a limitation that may be overcome by targeting functional protein domains 43 . Furthermore, there is evidence that Cas9 and shRNA screens identify nonoverlapping gene sets and may have different falsepositive or false-negative results 64 . Although Cas9 knockout screening is an enormously valuable LOF screening method, shRNA and CRISPRi screening may complement Cas9 knockout screening to further investigate complex biological questions.
Experimental design screening strategies
In general, there are two formats for conducting a screen: arrayed and pooled. For arrayed screens, individual reagents are aliquotted into separate wells in multiwell plates. This format allows for measuring of a diverse range of phenotypes such as fluorescence and luminescence, or even for direct imaging of cellular phenotypes 2,65-67 , but it is costly and time-consuming. An alternative format, and one that has been widely used for Cas9-based screens, is pooled screening, in which pooled lentiviral libraries are transduced at a low multiplicity of infection (MOI) to ensure that most cells receive only one stably integrated RNA guide. After the screen is complete, deep sequencing of the sgRNAs in the bulk genomic DNA identifies changes in the sgRNA distribution due to the applied screening selection pressure. As a result, pooled screens are less expensive and timeintensive than arrayed screens, but they are generally limited to growth phenotypes or to florescence-activated cell sorting (FACS)-selectable phenotypes. These can be categorized as positive (e.g., resistance to a drug, toxin or pathogen), negative (e.g., essential genes, toxicity), or marker gene selection (e.g., reporter gene expression) (Box 1).
Regardless of the type of screening selection, next-generation sequencing (NGS) is used to compare the number of reads for each sgRNA in the perturbed experimental condition relative to a control to identify candidate genes for validation. For positiveand negative-selection screens, the experimental and control conditions may be the same infection replicate treated with drug and vehicle, respectively, or analyzed at two different time points. Figure 2 | Timeline and overview of experiments. Genome-scale Cas9 knockout and transcriptional activation screens begin with the construction of a plasmid library encoding the effector protein and sgRNAs. These plasmid libraries are packaged into lentivirus and then transduced into the cell type of interest to generate stably expressing lines for the screen, along with an accessory transcriptional activator complex (MS2-p65-HSF1) lentivirus for the case of activation screening. A selection pressure is applied depending on the nature of the screen, and at given time points genomic DNA is harvested. The sgRNA regions (colored bars) are amplified from genomic DNA and then analyzed by next-generation sequencing followed by statistical analyses (e.g., RIGER) to identify candidate genes. Candidate genes are then validated by various forms of analysis, including testing of individual sgRNAs for the screening phenotype, indel formation by targeted sequencing, and transcript upregulation by qPCR. Blast, blasticidin; Puro, puromycin.
For marker gene selection screens, during FACS the cells with the highest and lowest marker gene expressions are selected for the experimental and control conditions. Design and selection of the sgRNA library. Although each sgRNA library is computationally designed for a specific purpose, the basic design process is consistent across libraries. First, the genomic regions of interest for targeting the sgRNA library are identified based on known sgRNA targeting rules (e.g., 5′ conserved exons for gene knockout; upstream or downstream of the transcriptional start site for transcriptional activation or repression, respectively). Second, all possible sgRNA targets with the Cas9 ortholog-specific protospacer adjacent motif are identified and selected based on four criteria: (i) minimization of off-target activity, (ii) maximization of on-target activity, (iii) avoidance of homopolymer stretches (e.g., AAAA, GGGG) and (iv) GC content. Recent work has begun to elucidate the features that govern sgRNA specificity and efficiency 41, 47 . Although specificity and efficiency will probably vary across experimental settings, false-positive sgRNAs in screens can still be mitigated by including redundant sgRNAs in the library and requiring multiple distinct sgRNAs targeting the same gene to display the same phenotype when identifying screening hits. Once the targeting sgRNAs have been chosen, additional nontargeting guides that do not target the genome should be included as negative controls. Nontargeting guides are critical to evaluating the noise and success of a screen. At the end of the screen, top hit-targeting guides in the experimental condition should be significantly enriched or depleted as compared with those in the control condition, whereas the nontargeting guides should remain relatively unchanged between the experimental and control conditions. We provide several genome-scale libraries for knockout and activation screening through Addgene (see REAGENTS). For knockout screening, the GeCKO v2 libraries target the 5′ conserved coding exons of 19,050 human or 20,611 mouse coding genes with 6 sgRNAs per gene (Fig. 3a) 68 . In addition to targeting coding genes, the GeCKO v2 libraries also target 1,864 human miRNAs or 1,175 mouse miRNAs with four sgRNAs per miRNA. Each species-specific library contains 1,000 nontargeting control sgRNAs. The GeCKO library is available in a 1-vector (lentiCRISPR v2) or 2-vector (lentiCas9-Blast and lentiGuide-Puro) format (Fig. 3b) . For activation screening, the SAM libraries target the 200-bp region upstream of the transcriptional start site of 23,430 human or 23,439 mouse RefSeq coding isoforms with three sgRNAs per isoform (Fig. 3c) 30 . The library must be combined with additional SAM effectors in a 2-vector (lentiSAM v2 and lentiMPH v2) or 3-vector (lenti dCAS-VP64_Blast, lentiMPH v2, and lenti sgRNA(MS2)_Puro or lenti sgRNA(MS2)_Zeo) format (Fig. 3d) . Both GeCKO v2 and SAM libraries prioritize sgRNAs with minimal off-target activity.
For designing custom libraries, we have provided a Python script (Supplementary Data 1) that generates sgRNAs targeting a set of genes at specified genomic regions. The script prioritizes sgRNAs with fewer potential off-target sites by accounting for position and distribution of mismatches between the candidate spacer sequence and similar sites in the genome 59 . One can readily adapt this Python script to design libraries for different genomes, nucleases, or regions of interest such as noncoding regions for saturated mutagenesis screening or protein functional domains. In cases in which a subset of genes is known to be involved in the screening phenotype and/or when the cell number is limited, one
Box 1 | Different types of selection applicable to CRISPR screens
Before setting up a screen, it is important to determine the type of screening selection based on the phenotype of interest and available selection pressures for the screen, as illustrated below:
Positive selection screens rely on enrichment of sgRNAs for genetic perturbations that produce the screening phenotype as a result of cell proliferation. These typically have the highest signal-to-noise ratio compared with other types of screens, because the number of phenotypically relevant sgRNAs increases relative to the rest of the sgRNAs. On the other hand, negative selection screens involve depletion of sgRNAs that correspond to the phenotype due to cell death. However, for a large number of screens, the phenotype of interest will not result in cell proliferation or cell death and thus the phenotypically relevant sgRNAs are not enriched or depleted. For these phenotypes, the screen may be read out by capturing sgRNAs that produce changes in marker gene protein expression using either endogenous-tagged fluorescent proteins or highly specific antibodies followed by FACS.
can consider performing a targeted screen that captures a subset of the genes in the genome-scale screens provided. We have included a Python script (Supplementary Data 2) for isolating the sgRNA target sequences corresponding to the genes in the targeted screen and adding flanking sequences for cloning. In addition, one can consider adapting the sgRNA library plasmid backbone to the needs of the screen. For instance, when screening in vivo in complex tissues, one can use a cell-type-specific promoter to ensure that only the cell type of interest is perturbed. To select for successful transduction by FACS, one can replace the antibiotic selection marker with a fluorescent marker. For these situations, we provide below a protocol for cloning a custom sgRNA library.
Approaches for sgRNA library construction and delivery. Throughout the sgRNA library cloning and amplification process, it is important to minimize any potential bias that may affect screening results. For example, the number of PCR cycles in the initial amplification of the pooled oligo library synthesis should be limited to prevent introducing bias during amplification. Scale each step of the cloning procedure provided according to the size of the library to reduce loss of sgRNA representation. After sgRNA library transformation, limit the growth time to avoid intercolony competition, which can result in plasmid amplification bias. Here we provide a protocol and accompanying Python script (Supplementary Data 3) for assessing sgRNA library distribution by NGS before screening.
Depending on the desired application, the sgRNA library can be delivered with lentivirus, retrovirus, or adeno-associated virus (AAV). Lentivirus and retrovirus integrate into the genome, whereas AAV does not integrate, and thus for screening, AAV delivery is limited to nondividing cells. By contrast, retrovirus transduces only dividing cells. In addition, AAV has a smaller insert size capacity as compared with lentivirus and retrovirus. As a result, to date most of the screens have relied on lentiviral delivery and we have provided two methods for lentivirus production and transduction.
Selection.
As the parameters for each screen differ according to the screening phenotype, in lieu of providing a protocol for screening selection, we have outlined general considerations for setting the relevant screening parameters, as well as technical advice for carrying out a screening selection, in Box 2. Additional in vivo screening considerations are described in Box 3. We also provide guidelines for saturated mutagenesis screening design and analysis in Box 4.
Analysis of screening results. For examples of anticipated results, we provide data from genome-scale knockout and transcriptional activation screening for genes that confer BRAF inhibitor vemurafenib (PLX) resistance in a BRAF V600E (A375) cell line 30, 37 . As a result of the screening selection pressure, at the end of a successful screen, the sgRNA library distribution in the experimental condition should be more skewed as compared with the baseline and control conditions, with some sgRNAs enriched and others depleted (as assayed by NGS) (Fig. 4a,b) . The targeting sgRNA representation should be more skewed as compared with the nontargeting sgRNA representation, which should be relatively unchanged. In addition, the relative enrichment or depletion of sgRNAs between the experimental and control conditions should correlate between different infection replicates. Depending on the type of screen (positive, negative or marker gene selection), the enrichment or depletion of sgRNAs will be used to identify candidate genes that confer the screening phenotype. Screening analysis methods such as RNAi gene enrichment ranking (RIGER), redundant siRNA activity (RSA), model-based analysis of genome-wide CRISPR/Cas9 knockout (MAGeCK) and STARS typically select candidate genes with multiple enriched or depleted sgRNAs to reduce the possibility that the observed change in sgRNA distribution was due to off-target activity of a single sgRNA 47, [69] [70] [71] . RIGER ranks sgRNAs according to their enrichment or depletion, and, for each gene, examines the positions of the sgRNAs targeting that gene in the ranked sgRNA list 69 . The algorithm then assesses whether the set of positions is biased toward the top of the list, using a Kolmogorov-Smirnov statistic, and calculates an enrichment score and gene ranking based on a permutation test. RSA is similar to RIGER, except that it assigns statistical significance based on an iterative hypergeometric distribution formula 70 . Another screening analysis method, MAGeCK, assesses the statistical significance of sgRNA rankings using the negative binomial model before
Box 2 | Considerations for setting screening parameters
Optimal screening parameters should maximize the difference in sgRNA distribution between the experimental and control conditions. Selection conditions such as drug dosage or FACS bin cutoff should be predetermined, if possible, using positive and negative controls from the literature and should be set to the level at which the greatest difference is observed. As for determining the duration of the screen, collection of time points throughout the screen helps identify the best time point for harvesting and analyzing the screen. These time points are also informative for assessing whether it is necessary to increase the duration to enhance the difference between experimental and control conditions. Throughout the screen, it is imperative to maintain sufficient coverage to avoid losing sgRNA representation or biasing the screening results. Try to maintain sufficient coverage (>500 cells per sgRNA) in the library during library transduction, screening selection, and screening harvest. In addition, we recommend 2-4 infection replicates per screen to account for stochastic noise. Increase the coverage and number of infection replicates if the screening selection is noisy. Finally, consistency of screening conditions such as sgRNA representation and passaging reduces the variability between infection replicates. . This ex vivo screen identified many known, as well as novel, regulators of LPS response. When performing an ex vivo screen, it is necessary to be able to obtain enough cells to maintain library representation, deliver appropriate reagents to the cells, and culture the cells for long enough to perform the screen. In cases in which these conditions cannot be met, adapt the screening strategy by, for instance, reducing the library size to capture a subset of genes.
In vivo screening is performed with either a) transduction of cells in vitro followed by in vitro cell transplantation, or b) direct transduction of tissues in vitro. The first strategy was demonstrated by Chen et al., whereby a cancer cell line was transduced with a CRISPR knockout library and injected subcutaneously in immunocompromised mice 42 . NGS analysis of harvested tumors identified known and novel tumor suppressors associated with tumor growth and metastasis. The main challenge of this approach is engrafting cells in vitro. Special care must be taken to ensure that the library is not only maintained upon infection of cells in vitro but also after engraftment of cells in vitro. While it is not required to maintain library representation on a per animal basis, a sufficient number of animals should be used such that library representation is maintained for each experimental cohort. Because the engraftment efficiency and time of engraftment can change for each application it is necessary to sequence the library at several time points after injection of cells in vivo. The optimal time point is one where engraftment is complete and selection (i.e. proliferation, death, or migration) has not yet occurred. Identifying this time point is critical as it is used as a reference to identify enriched and/or depleted perturbations.
For the second method of in vitro screening, special considerations will vary widely depending on the specific animal model, tissue, cell type, developmental time point, or biological question. Thus, each screen should be uniquely designed. In addition to the screening considerations outlined previously, the additional challenge for this strategy is the delivery of reagents in a complex environment while maintaining library representation and also infecting cells at a low MOI. Beyond specific circumstances, it may not be feasible to achieve appropriate cell numbers suitable for a genome-scale library. In these cases it is recommended to design smaller, targeted libraries with a specific hypothesis in mind. The complexity of the in vivo environment makes it difficult to meet the critical requirements for performing an informative screen. In assessing whether a direct in vivo screening strategy is feasible for any particular application, consider these guiding questions: 1) Is there a delivery strategy for infecting the target cells at low MOI? 2) Can enough of the target population be infected and purified to maintain library representation? 3) Can a reference population be identified before the guide RNA abundance changes? identifying positively and negatively selected genes and pathways using a robust ranking aggregation algorithm 71 . STARS scores genes using the probability mass function of a binomial distribution and generates false-discovery rates 47 .
These screening analysis methods can be adapted for noncoding screens by partitioning the noncoding region into smaller sections and assigning sgRNAs to each section. As indels can be of varying lengths, sections with consistent enrichment or depletion of multiple sgRNAs indicate the presence of a potentially functional regulatory element. In this protocol, we describe in detail how to identify candidate genes using RIGER. Each candidate gene identified by the screening analysis should have multiple significantly enriched or depleted sgRNAs in the experimental condition relative to the control (Fig. 4c,d ). The RIGER P values of the candidate genes should also be substantially lower than those of the rest of the genes (Fig. 4e,f) .
Validation of candidate genes. Given that the screening process can be noisy and the analysis produces a ranked list of candidate genes, it is necessary to verify that perturbation of the identified candidate genes confers the phenotype of interest. For validation, each of the sgRNAs that target the candidate gene can be individually cloned into the plasmid backbone of the sgRNA library and validated for the screening phenotype. In addition, the perturbation induced by each sgRNA, indel rate, and transcriptional activation for knockout and activation screening, respectively, will be quantified to establish a phenotype-to-genotype relationship.
Indel rates can be detected either by the SURVEYOR nuclease assay or by NGS. Compared with SURVEYOR, which we have described previously 72 , NGS is more suitable to sampling a large number of sgRNA target sites and therefore is described here. For measuring indel rates, it is important to design primers situated at least 50 bp from the target cleavage site to allow for the detection of longer indels. Our protocol for targeted NGS outlines a twostep PCR in which the first step uses custom primers to amplify the genomic region of interest and the second step uses universal, barcoded primers for multiplex deep sequencing on the Illumina platform. Relative to the one-step PCR method recommended for preparing sgRNA libraries for NGS, the two-step PCR method is more versatile and less costly for assessing many different target sites because custom primers for each target site can be readily combined with different universal, barcoded primers.
After NGS, indel rates can be calculated by running the provided Python script (Supplementary Data 4), which implements two different algorithms. The first aligns reads using the RatcliffObershelp algorithm and then finds regions of insertion or deletion from this alignment 73 . The second method, adapted from the Geneious aligner, scans k-mers across the read and maps the alignment to detect indels 74 . In practice, the Ratcliff-Obershelp alignment algorithm is more accurate, whereas the k-mer-based alignment algorithm is faster. These indel rates are then adjusted to account for background indel rates via a maximum likelihood estimation (MLE) correction 59 . The MLE correction models the observed indel rate as a combination of the true indel rate resulting from Cas9 cleavage and a separately measured background indel rate. The true indel rate is that which maximizes the probability of the observed read counts under the assumption that they obey a binomial distribution with the background rate.
Box 4 | Designing and analyzing a saturated mutagenesis screen
Although most pooled CRISPR screens to date have focused on knockout or activation of protein-coding genes, CRISPR screens can also be used to identify functional elements in noncoding regions of the genome such as enhancers or repressors. These functional elements are often inferred using biochemical hallmarks associated with function (e.g., chromatin accessibility, transcription-factor binding sites, or post-translational histone modifications). By contrast, CRISPR screens enable direct testing of how mutagenesis at a specific noncoding site affects phenotype.
Several strategies can be used to design libraries to target noncoding regions. To enable understanding of the regulation of a particular gene, tiling mutagenesis libraries were designed to include many or all possible target sites within a noncoding region near a gene 53, 56, 57 . This allows unbiased identification of all regulatory elements in regions near a gene that has already been established to be important for the screening phenotype, as illustrated below:
Another approach is to design the library to target all instances across the genome of a specific biochemical hallmark, such as all binding sites of a transcription factor such as p53 (ref. 54) . With this kind of library, it is possible to identify specific binding sites or regulatory elements associated with a phenotype of interest.
As with screening the coding genome, a key factor in assessing the performance of the screen is to find multiple sgRNAs targeting the same element that are enriched or depleted together. In coding regions, this is straightforward, as the library is designed to have multiple sgRNAs that target the same gene. In noncoding regions, the same principle of consistent enrichment or depletion can be applied to multiple sgRNAs that target neighboring regions, as the indels are of variable length. Once a functional element is validated using multiple sgRNAs with adjacent target sites, expression of nearby genes and potential mechanisms such as alterations in transcription factor binding at the site can be used to gain further insight into biological mechanisms. Measurement of transcriptional activation usually entails isolation of RNA, reverse transcription of the RNA to cDNA, and quantitative PCR (qPCR). Various methods have been described for each step of the process. In this protocol, we provide a method for reverse transcription followed by qPCR that is rapid, high-throughput, and cost-effective and thus ideal for quantifying fold upregulation for validation. Our method involves direct lysis of cells grown on a 96-well plate, followed by reverse transcription and TaqMan qPCR. TaqMan-based detection is more specific and reproducible than SYBR-based detection because it relies on a fluorogenic probe specific to the target gene, whereas SYBR depends on a dsDNA-binding dye. TaqMan also allows for multiplexing with control probes that measure housekeeping gene expression as a proxy for total RNA concentration.
After validation of the screening phenotype and perturbation, we recommend verifying downregulation or upregulation of protein expression for knockout or transcriptional activation screening, respectively. Immunohistochemistry and western blotting are two of the most common methods for verifying protein expression. Immunohistochemistry requires fixing the validation cell lines and detecting the target protein using a specific antibody, whereas western blotting involves harvesting protein and separating by electrophoresis before staining with the specific antibody. Although immunohistochemistry provides additional information on protein localization, it often requires a more specific antibody than western blotting because proteins are not separated by size. Thus, western blotting is preferable for verifying protein expression of candidate genes.  crItIcal An endotoxin-free plasmid purification kit is important for avoiding endotoxicity in virus production and mammalian cell culture.
MaterIals

REAGENTS
Other endotoxin-free plasmid purification kits, such as the Qiagen Plasmid Plus Midi Kit, may be used as substitutes.
Next-generation sequencing
Primers (Primers for amplifying the library for NGS are listed in Table 3 . Primers for amplifying indels for NGS are listed in The custom first-round primer consists of a universal sequence followed by an optional stagger sequence (1-10 additional random nucleotides for introducing diversity in low-diversity NGS libraries) and the custom priming site designed to amplify the 100-to 300-bp region centered around the sgRNA cut site. Second-round universal, barcoded primers amplify the first-round PCR products. For routine cell line culture and maintenance, D10 can be further supplemented with 1× penicillin-streptomycin. Store the medium at 4 °C for up to 1 month. mTeSR1 medium For culture of human embryonic stem cells (hESCs), prepare mTeSR1 medium by supplementing it with the supplement supplied with the medium and 100 µg ml −1 Normocin. Prepared medium can be stored at 4 °C for up to 2 months. Proteinase K, 300 U ml −1 Resuspend 25 mg of proteinase K in 2.5 ml of 10 mM Tris, pH 8.0, for 10 mg ml −1 (300 U ml −1 ) proteinase K. Store it at 4 °C for up to 1 year. Deoxyribonuclease I, 50 KU ml −1 Resuspend 50 KU of deoxyribonuclease I in a solution containing 50% (vol/vol) glycerol, 10 mM CaCl 2 , and 50 mM Tris-HCl (pH 7.5) for 50 KU ml −1 of deoxyribonuclease I as follows. Store the solution at −20 °C for up to 2 years.
Component
Amount (ml) Final concentration
Tris-HCl, pH 7. Total 5,000 (iii) Design custom library. Download the genome 2bit file that the target gene coordinates correspond to from the UCSC Genome Browser (http://hgdownload.cse.ucsc.edu/downloads.html). The genome 2bit file will be used to construct a database of off-target scores based on the position and distribution of mismatches between each spacer sequence and similar sequences in the genome. For each region in the target genes .csv file, the Python script will identify potential sgRNAs and select a specified number of sgRNAs with fewer potential off-target sites using this database for the custom library. To design a custom library, run Python design_library.py with the following optional parameters: Used to specify the type of library and add the respective flanking sequences to the spacers for the oligo library synthesis Neither When designing sgRNAs against large genomic regions (>50 kb), we recommend splitting the target-gene .csv file into several files containing different subsets of the target genes to parallelize the library design process and minimize run time. After running design_library.py, the spacers that target the specified genomic coordinates will be written to an output .csv file. When designing a new custom library targeting the same genomic regions as a previous custom library, using the previously constructed off-target database can dramatically reduce the script execution time. If '-gecko' or '-sam' is specified, the full oligo library sequence containing the spacers and respective flanking sequences for synthesis will be in the last column. After running design_targeted_library.py, the subset of spacers for the target genes will be written to an output .csv file. If '-gecko' or '-sam' is specified, the full oligo library sequence containing the spacers and respective flanking sequences for synthesis will be in the last column.
(B) Generation of a targeted library from an existing library (i)
2| Synthesize the oligo library as a pool on an array through a DNA synthesis platform such as Twist Bioscience or CustomArray. Synthesis typically requires 2-4 weeks, depending on the size of the oligo library. Wrap the pooled oligos in Parafilm and store them at −20 °C.  crItIcal step Limit the number of PCR cycles to 20 cycles during amplification to reduce potential biases introduced during amplification.
5|
After the reaction is complete, pool the PCR reactions and purify the PCR product using the QIAquick PCR Purification Kit according to the manufacturer's directions. Use a NanoDrop UV spectrophotometer to quantify the product.
6| Run the PCR-purified oligo library from
Step 5 on a gel along with a 50-bp ladder: cast a 2% (wt/vol) agarose gel in TBE buffer with SYBR Safe dye. Run half of the oligo library in the gel at 15 V cm −1 for 45 min.  crItIcal step Run on a 2% (wt/vol) agarose gel for long enough to separate the target library (140 bp) from a possible primer-dimer of ~120 bp. Under the optimized PCR conditions suggested above, the presence of primer-dimers should be minimal.
7| Gel-extract the purified PCR product using the QIAquick Gel Extraction Kit according to the manufacturer's directions and use a NanoDrop UV spectrophotometer to quantify the final product.
8|
Restriction digest of plasmid backbone. Digest the desired library plasmid backbone with the restriction enzyme Esp3I (BsmBI), which cuts around the sgRNA target region. Refer to the master mix setup below for the reaction ratios: 9| Prepare aliquots of 20-µl reactions from the master mix and incubate the restriction digest reaction at 37 °C for 1 h.
10|
After the reaction has completed, pool the restriction digest reactions from Step 9 and run the entire pooled restriction digest reaction on a gel. Cast a 2% (wt/vol) agarose gel in TBE buffer with SYBR Safe dye and run the reaction in the gel at 15 V cm −1 for 30 min. Gel-extract the library plasmid backbone using the QIAquick Gel Extraction Kit according to the manufacturer's protocol and use a NanoDrop UV spectrophotometer to quantify the product. Note that the GeCKO library backbones contain a 1,880-bp filler sequence, which should be visible as a dropout. The SAM library backbones do not contain a filler sequence, and the expected dropout of 20 bp is usually not readily visible.
11|
Gibson assembly. Set up a master mix for the Gibson reactions on ice according to the reaction ratios below. Be sure to include reactions without the sgRNA library insert as a control.  crItIcal step In addition to concentrating the library, purification by isopropanol precipitation removes salts from the Gibson reaction that can interfere with electroporation.
14|
Vortex and incubate the mixture at room temperature for 15 min and centrifuge at >15,000g for 15 min at room temperature to precipitate the plasmid DNA. The precipitated plasmid DNA should appear as a small light blue pellet at the bottom of the microcentrifuge tube.
15|
Aspirate the supernatant and gently wash the pellet twice without disturbing it using 1 ml of ice-cold (−20 °C) 80% (vol/vol) ethanol in UltraPure water.
16|
Carefully remove any residual ethanol and air-dry for 1 min. 20| After the 1-h recovery period, pool electroporated cells and mix well by inverting.
17|
21|
Prepare a dilution for calculating the transformation efficiency. To prepare the dilution mix, add 10 µl of the pooled electroporated cells to 990 µl of LB medium for a 100-fold dilution and mix well. Then add 100 µl of the 100-fold dilution to 900 µl of LB medium for a 1,000-fold dilution and mix well.
22|
Plate 100 µl of the 1,000-fold dilution on a prewarmed standard LB agar plate (100-mm Petri dish, ampicillin from Step 19) . This is a 10,000-fold dilution of the full transformation that will be used to estimate the transformation efficiency. 
28|
Harvest colonies from the LB agar plates. Pipette 10 ml of LB medium onto each large LB agar plate or 1 ml of LB medium onto each standard LB agar plate. Gently scrape the colonies off with a cell spreader, and transfer the liquid with scraped colonies to a 50-ml Falcon tube.
29| For each LB agar plate, repeat
Step 28, for a total of 2 LB medium washes, to capture any remaining bacteria.
30|
Calculate the number of maxipreps needed by measuring the OD 600 value of the harvested bacterial suspension as follows: number of maxipreps = OD 600 value · (total volume of suspension)/1,200. Perform maxipreps of the amplified sgRNA library by using the Macherey-Nagel NucleoBond Xtra Maxi EF Kit according to the manufacturer's directions.  crItIcal step Using an endotoxin-free plasmid purification kit is important for avoiding endotoxicity in virus production and mammalian cell culture. To ensure that the plasmid preparation is endotoxin-free, it is important to dilute the bacterial suspension to an OD 600 value within the linear range of the spectrophotometer, typically ~0.1-0.5, and measure the OD 600 value of the dilution. Then multiply the OD 600 value by the dilution factor to obtain the OD 600 value of the bacterial suspension. Approximately one maxiprep is needed for two densely plated large LB agar plates.
31|
Pool the resulting plasmid DNA and use a NanoDrop UV spectrophotometer to quantify the product. Maxiprepped sgRNA library can be aliquotted and stored at −20 °C for at least 1 year. 34| After the reaction is complete, pool the PCR reactions and purify the PCR product by using the QIAquick PCR Purification Kit according to the manufacturer's directions.
35|
Quantify the purified PCR product and run 2 µg of the product on a 2% (wt/vol) agarose gel. Successful reactions should yield a ~260-to 270-bp product for the knockout library and a ~270-to 280-bp product for the activation library. Perform gel extraction using the QIAquick Gel Extraction Kit according to the manufacturer's directions.  pause poInt Gel-extracted samples can be stored at −20 °C for several months.
36|
Quantify the gel-extracted samples using the Qubit dsDNA HS Assay Kit according to the manufacturer's instructions.
37|
Sequence the samples on the Illumina MiSeq or NextSeq according to the Illumina user manual, with 80 cycles of read 1 (forward) and 8 cycles of index 1. We recommend sequencing with a 5% PhiX control on the MiSeq or a 20% PhiX control on the NextSeq to improve library diversity; we recommend aiming for a coverage of >100 reads per sgRNA in the library.
38|
Analyze sequencing data with count_spacers.py. We provide a Python script for analyzing the NGS results for the sgRNA representation (supplementary Data 3). Install Python 2.7 (https://www.python.org/downloads/) and biopython (http://biopython.org/DIST/docs/install/Installation.html). Prepare a .csv file containing the guide spacer sequences, with each line corresponding to one sequence.
39|
To determine the spacer distribution, run python count_spacers.py with the following optional parameters: After running count_spacers.py, spacer read counts will be written to an output .csv file. Relevant statistics, including the number of perfect guide matches, nonperfect guide matches, sequencing reads without key, number of reads processed, percentage of perfectly matching guides, percentage of undetected guides, and skew ratio will be written to statistics.txt. An ideal sgRNA library should have >70% perfectly matching guides, <0.5% undetected guides, and a skew ratio of less than 10.  crItIcal step The human SAM libraries do not have a guanine before the guide spacer sequence, so make sure to run the script with the parameter -no-g when analyzing those libraries.
? trouBlesHootInG lentivirus production and titer • tIMInG 1-2 weeks 40| Perform an antibiotic kill curve. Before lentivirus production and titer, we recommend performing a kill curve for the antibiotic used to select the sgRNA library and additional necessary components on the relevant cell line for screening. To do so, seed cells at 10% confluency in media containing a range of antibiotic concentrations typically used for selection. For the no-antibiotic-selection control well, replace the medium with normal mTeSR1 medium. Refresh the mTeSR1 medium with and without antibiotic selection every day until the plate is ready for the next step. 
60|
Centrifuge the mixture at 500g for 5 min at room temperature. Discard the flow-through.
61| Add 2 ml of DNA Wash Buffer and centrifuge at 500g for 5 min at room temperature. Discard the flow-through and repeat for an additional wash.
62|
Remove the reservoir from the Zymo-Spin V column and transfer the column to a 2-ml collection tube. In a microcentrifuge, spin at the maximum speed (>12,000g) for 1 min at room temperature to remove residual wash buffer.
63|
Transfer the Zymo-Spin V column to a 1.5-ml microcentrifuge tube. Add 150 µl of elution buffer, wait for 1 min, and spin at the maximum speed (>12,000g) for 1.5 min at room temperature to elute the purified PCR reaction.
64|
Pool the purified PCR reactions and quantify. Refer to Steps 37-39 for NGS analysis of the sgRNA distribution.
For screening NGS analysis, we recommend aiming for a coverage of >500 reads per sgRNA in the library.
65| Analysis of screening results with RIGER.
Before RIGER analysis, determine the sgRNA fold change due to screening selection. For each biorep of screening experimental or control condition, add a pseudocount of 1 to the NGS read count of each sgRNA and normalize by the total number of NGS read counts for that condition. To obtain the sgRNA fold change, divide the experimental normalized sgRNA count by the control and take the base 2 logarithm.
68|
Once the RIGER analysis has completed, export the gene rank data set. Determine the top candidate genes based on either the overlap or the average ranking between the screening bioreps. 93| Perform a PCR using the same cycling conditions as described in
Step 91.
94|
After the reaction is complete, run 5 µl of each amplified target on a gel to verify successful amplification of a single product at the appropriate size. Cast a 2% (wt/vol) agarose gel in TBE buffer with SYBR Safe dye and run the gel at 15 V cm −1 for 30 min.
? trouBlesHootInG 95| Pool the PCR products and purify the pooled product using the QIAquick PCR Purification Kit, according to the manufacturer's instructions.  crItIcal step Because of variable PCR efficiencies and product lengths, pooling without normalization may result in variation in NGS representation. When pooling without normalization, aim for 20,000-40,000 reads per sgRNA during sequencing. Alternatively, if sequencing reads are limited, consider purifying each barcoded PCR product separately, using a NanoDrop UV spectrophotometer to quantify the products, and normalizing them to the same concentration before pooling.
96|
Run the pooled PCR product on a 2% (wt/vol) agarose gel as described in
Step 94, and gel-extract the appropriately sized bands using the QIAquick Gel Extraction Kit according to the manufacturer's directions.  pause poInt Gel-extracted product can be stored at −20 °C for several months. For processing individual samples, such as in the case of parallelization, use the command python calculate_indel.py -sample <sample name> to produce a file <sample name>_out.csv. Combine individual sample files by calling python calculate_indel.py --combine. After running calculate_indel.py, calculated indels will be in the output file, which also contains counts of reads that matched perfectly, failed to align, or were rejected because of quality, or had miscalled bases/replacements. There will also be three columns corresponding to the MLE-corrected indel rate, as well as the upper and lower bounds for the 95% confidence interval of indels. Reduce the number of PCR cycles during oligo amplification; increase the number of reactions throughout cloning, and ensure there are >500 colonies per guide during library amplification; contact your synthesis company or core to discuss your results
97|
100|
51
Low survival following Lipofectamine transfection
Cell density at transfection was <75%; failure to replace medium within 6 h post transfection
Ensure even plating and a cell density of 80-90% during transfection. Replace the medium 4 h after transfection. The cell density should not be <80% at the time of lentivirus harvest (continued) 
antIcIpateD results
As a reference for screening results, we provide data from genome-scale knockout and transcriptional activation screens for genes that confer BRAF inhibitor vemurafenib (PLX) resistance in a BRAF V600E (A375) cell line 30, 37 . After applying vemurafenib selection, the sgRNA library distribution in the experimental condition, which is measured by NGS, is more skewed than the baseline and vehicle control conditions, with some sgRNAs enriched and others depleted (Fig. 4a,b) . SgRNAs targeting genes involved in vemurafenib resistance are enriched because they provide a proliferation advantage upon vemurafenib treatment. RIGER analysis of enriched sgRNAs in the vemurafenib condition relative to the control identified several candidate genes responsible for resistance. Each candidate gene has multiple significantly enriched sgRNAs (Fig. 4c,d) and P values that are substantially lower than those for the rest of the genes (Fig. 4e,f) .
Box 6 | Frequently asked screening questions from the CRISPR Forum
The following questions are selected from the CRISPR Discussion Forum (https://groups.google.com/forum/#!forum/crispr). Q1: Can I use liquid culture amplification of the library rather than solid plates? We recommend using plates because liquid culture can generate more bias in the plasmid library. β-lactamase, the enzyme responsible for ampicillin resistance, is secreted, and eventually in liquid culture the selective pressure on the plasmid is decreased, causing bias. In addition, it is more difficult for certain clones to predominate on solid plates because they are spatially limited in growth and each clone is spatially separated to prevent potential intercolony competition. However, it is important to note that some studies have had success with liquid culture amplification 45 . Q2: Is there a difference between using HEK293FT and HEK293T cells for lentivirus production? Yes, HEK293FT cells are generally better for lentivirus production. HEK293T cells are a cell line stably expressing the SV40 large T antigen, which helps to boost protein production of expression constructs containing the SV40 enhancer element. HEK293FT cells are a fast-growing, highly transfectable clonal derivation of HEK293T cells that yield a higher lentivirus titer than the HEK293T line. Q3: For activation, how do I design guides relative to the TSS of the transcript? In addition, can I expect these guides to work with transient transfection of dCas9-VP64 and MS2-VP65-HSF1 plasmids?
The transcriptional start site (TSS) is the beginning of the 5′ UTR. The UCSC Table Browser (https://genome.ucsc.edu/ cgi-bin/hgTables) is a good resource for TSS annotations. We have observed the most robust transcriptional upregulation when sgRNAs are designed to target the 200-bp region upstream of the TSS. We have created a web tool using these parameters to simplify activation sgRNA design for human and mouse genes (http://sam.genome-engineering.org/database/). SAM is highly robust and should yield significant activation levels even in the case of transient transfection 30 . Q4: What are important considerations for NGS PCR amplification? When designing primers, it is important to include stagger between the primer-binding site and the Illumina adaptor sequence such that the sequencing regions of different amplicons are offset, improving the sequence diversity and quality. For genomic DNA amplification, it can be helpful to optimize the DNA input for the sequencing readout PCR step. Generally, it is recommended for any given instance of the screen to titrate the DNA input and use the highest possible input without a decrease in the target band intensity. It is critical to minimize amplification bias. The optimal cycle number should always be determined by performing PCR with a series of different cycle numbers (e.g., 5, 10 and 15) and identifying the lowest cycle number that generates a visible band by gel electrophoresis. Avoid conditions that yield additional bands at higher cycle numbers. Q5: My screening design requires too many cells. Can I reduce the coverage?
We recommend screening at a coverage of >500 cells per sgRNA. Because there is always variability in the copy number of each sgRNA in a given library, it is important to have high coverage to overcome any bias. If it is impossible to screen at this coverage (e.g., insufficient primary cells present or cells are difficult to transduce), consider screening with a smaller, targeted library. Q6: How do you measure the quality of a cloned plasmid library? While there are many methods for determining the quality of a library, we typically use the following measures for a sequencing depth of >100 reads per sgRNA: 1. Overall representation: <0.5% of sgRNAs have dropped out with no reads. 2. Library uniformity: <10-fold difference between the 90th percentile and the 10th percentile.
